The $450M Copaxone figure in #msg-67293937 takes into account the (less than certain) probability of success and the sharing of profits with NVS. The figure is probably near the low end of what’s reasonable, but I was trying to be conservative.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.